When
Where
Kreftforeningens vitensenter, Kongens gate 6, 0153 Oslo
Organizer
Norway has strong clinical expertise, patient access and infrastructure relevant for radiopharmaceutical and theranostics clinical trials. However, these capabilities are not always sufficiently visible, accessible, or coordinated across the ecosystem.
This meeting brings together hospitals, clinical researchers, emerging radiopharma companies, global pharma and ecosystem partners to learn from international examples, share recent initiatives, and discuss gaps and opportunities positioning Norway as a preferred destination for radiopharmaceutical trials.
14:00–14:05 Welcome by Caroline Stokke, OUS, Coordinator of the RLT and Theranostics Initiative
14:05–14:15 Welcome and framing: Purpose of the event series, complementarity with June 10 event (OCC and NERR)
14:15–14:55 International Keynote by Prof. Frederik Giesel, University Hospital Düsseldorf, "From Target to Treatment: A Clinician-Innovator's Journey & What the Next Generation of Theranostics Will Require"
14:55–15:55 "From Infrastructure to Impact: Clinical Initiatives and the Collaboration Opportunities They Create"
Speakers from Norway’s clinical milieu present initiatives at the intersection of nuclear medicine, oncology and radiopharmaceutical research, and how cross-disciplinary collaboration is expanding the country's capacity for radiopharmaceutical research and trials. They will discuss what these initiatives offer to the broader ecosystem and where opportunities for deeper partnership lie.
Introduction by Åse Bratland for NERR & Mona-Elisabeth Rootwelt-Revheim, Intervention Center, Oslo University Hospital:
15:55–16:10 Networking Coffee Break
16:10–17:10 Session 2: "From Pipeline to Partnership: What Industry Needs from Norway's Clinical Ecosystem"
Emerging Norwegian companies and global pharma present their R&D, their experience of the Norwegian clinical ecosystem, and what they need to accelerate or locate their next studies here. Together, their perspectives draw a clear picture of where Norway stands and what it would take to make it a preferred destination for radiopharmaceutical clinical trials.
Short talks by
17:10–17:30 Closing Panel: "From Insight to Action: Priorities for Norway's Radiopharma Clinical Ecosystem"
This closing panel brings together perspectives from the clinic, industry and investment to synthesise the day's key insights into concrete priorities and how these can be addressed jointly going forward.
17:30–17:35 Wrap-up (incl. outlook June 10th event)
17:35–18:30 Networking Evening
Hosted by Oslo Cancer Cluster and the National Expert Group for Radiotherapy Research (NERR) and supported by the Syklotronsenter.
The event is the first of two complementary ecosystem events in 2026 and potentially a start to a meeting series (co)hosted by different members and partners in the OUS / UiO RLT- and theranostics initiative coordinated by Caroline Stokke and initiated via the Oslo Science City Gravitational Fields Initiative.
The second event will be hosted by the Syklotronsenter and takes place on June 10th, 2026.
Contacts:
Jutta Heix, jh@oslocancercluster.no for OCC
Åse Bratland, BRT@ous-hf.no and Berit Bø, BBH@ous-hf.no for NERR
Prof. Dr. Frederik L. Giesel, MD, MBA, Chair, Department of Nuclear Medicine, University Hospital Düsseldorf
Prof. Frederik Giesel is one of Europe's leading clinical scientists in radiopharmaceutical oncology and theranostics. As Chair and Full Professor of Nuclear Medicine at University Hospital Düsseldorf (Heinrich-Heine-University), a position he has held since 2021, he leads one of Germany's foremost theranostics programs, integrating PSMA and FAPI-based diagnostics, radioligand therapy and early access to novel alpha-emitting agents in routine clinical and trial settings.
Prof. Giesel is co-inventor of FAPI-46, FAPI-74 and [¹⁸F]PSMA-1007, among the most widely used radiopharmaceutical tracers in clinical practice today and holds granted patents in more than 30 countries for PSMA- and FAP-targeting agents. He has been instrumental in translating these compounds from academic discovery at the German Cancer Research Center (DKFZ) and University Hospital Heidelberg through to licensed, commercially available agents, a journey spanning radiochemistry, GMP production, Phase I–III trials and regulatory approval. His publication record exceeds 300 peer-reviewed papers with an H-index of 75, with landmark contributions to FAPI PET/CT across tumor entities, PSMA radioligand therapy in prostate cancer, and the first standardized reporting framework for FAP-targeted imaging (FAP-RADS, 2025).
Beyond his clinical and scientific work, Prof. Giesel brings a direct and unusually complete understanding of the academia–industry interface, underpinned by an executive MBA from the Frankfurt School of Finance and Management. He has collaborated across the full development chain and serves as Co-Chair of the Scientific Advisory Board of the ICPO Foundation and as Scientific Advisor to Telix Pharmaceuticals, SOFIE Biosciences, ABX GmbH and Alpha Fusion. He is also Visiting Professor at Osaka University, reflecting the global reach of his translational research program.
Prof. Giesel´s Keynote Lecture will draw on his own innovation journey, from the earliest FAPI and PSMA discoveries through clinical translation, industry collaboration and commercial licensing sharing the lessons that shaped his approach to building a world-class theranostics program. He will offer a forward-looking perspective on where the field is heading novel targets beyond PSMA and FAP, the evolving choice between alpha and beta emitters, and the accelerating global innovation race in radiopharmaceuticals. For the Norwegian ecosystem, his talk will also address what this trajectory demands from clinical infrastructure and what it takes to be a relevant partner in an increasingly competitive international landscape.